Undergraduate Degree

  • Yale University , 2007 , New Haven , CT

Medical School

  • Harvard Medical School , 2011 , Boston , MA


  • Brigham and Women's Hospital and Massachusetts General Hospital , 2012 , Boston , MA


  • Brigham and Women's Hospital and Massachusetts General Hospital , 2015 , Boston , MA


  • Brigham and Women's Hospital and Massachusetts General Hospital , 2019 , Boston , MA


  • American Board of Genetics and Genomics
  • American Board of Medical Genetics and Genomics, Clinical Genetics
  • American Board of Obstetrics and Gynecology


Publications powered by Harvard Catalyst Profiles

  1. O'Connell AE, Guseh S, Lapteva L, Cummings CL, Wilkins-Haug L, Chan J, Peranteau WH, Almeida-Porada G, Kourembanas S. Gene and Stem Cell Therapies for Fetal Care: A Review. JAMA Pediatr. 2020 Jun 29. View abstract
  2. Guseh SH, Friedman KG, Wilkins-Haug LE. Fetal cardiac intervention-Perspectives from a single center. Prenat Diagn. 2020 03; 40(4):415-423. View abstract
  3. Guseh SH. Noninvasive prenatal testing: from aneuploidy to single genes. Hum Genet. 2020 Sep; 139(9):1141-1148. View abstract
  4. Guseh SH, Little SE, Bennett K, Silva V, Wilkins-Haug LE. Antepartum management and obstetric outcomes among pregnancies with Down syndrome from diagnosis to delivery. Prenat Diagn. 2017 Jul; 37(7):640-646. View abstract
  5. Guseh SH, Chen XP, Johnson NR. Can enriching emotional intelligence improve medical students' proactivity and adaptability during OB/GYN clerkships? Int J Med Educ. 2015 Dec 26; 6:208-12. View abstract
  6. Guseh SH, Little SE, Zera CA, Robinson JN. How Accurate Is the Dating of Scheduled 39-Week Deliveries? Am J Perinatol. 2016 Mar; 33(4):364-9. View abstract
  7. Guseh SH, Feinberg BB, Dawood HY, Yamamoto HS, Fichorova RN, Burwick RM. Urinary excretion of C5b-9 is associated with the anti-angiogenic state in severe preeclampsia. Am J Reprod Immunol. 2015 May; 73(5):437-44. View abstract
  8. Guseh S, Little S, Zera C, Robinson J. How accurate is the dating of scheduled 39-week deliveries? Obstet Gynecol. 2014 May; 123 Suppl 1:55S. View abstract
  9. Worley MJ, Guseh SH, Rauh-Hain JA, Esselen KM, Muto MG, Feltmate CM, Berkowitz RS, Del Carmen MG, Schorge JO, Horowitz NS. What is the optimal treatment for obese patients with advanced ovarian carcinoma? Am J Obstet Gynecol. 2014 Sep; 211(3):231.e1-9. View abstract
  10. Guseh SH, Rauh-Hain JA, Tambouret RH, Davis M, Clark RM, Boruta DM, Goodman A, Growdon WB, Schorge JO, del Carmen MG. Transitional cell carcinoma of the ovary: a case-control study. Gynecol Oncol. 2014 Mar; 132(3):649-53. View abstract
  11. Rauh-Hain JA, Guseh SH, Esselen KM, Growdon WB, Schorge JO, Horowitz NS, Krasner CN, del Carmen MG, Birrer MJ, Dizon DS. Patterns of recurrence in patients treated with bevacizumab in the primary treatment of advanced epithelial ovarian cancer. Int J Gynecol Cancer. 2013 Sep; 23(7):1219-25. View abstract
  12. Rauh-Hain JA, Oduyebo T, Diver EJ, Guseh SH, George S, Muto MG, del Carmen MG. Uterine leiomyosarcoma: an updated series. Int J Gynecol Cancer. 2013 Jul; 23(6):1036-43. View abstract
  13. Worley MJ, Guseh SH, Rauh-Hain JA, Williams KA, Muto MG, Feltmate CM, Berkowitz RS, Horowitz NS. Does neoadjuvant chemotherapy decrease the risk of hospital readmission following debulking surgery? Gynecol Oncol. 2013 Apr; 129(1):69-73. View abstract
  14. Guseh SH, Bradford LS, Hariri LP, Schorge JO. Ovarian angiosarcoma: Extended survival following optimal cytoreductive surgery and adjuvant chemotherapy. Gynecol Oncol Case Rep. 2012; 4:23-5. View abstract
  15. Coopey S, Smith BL, Hanson S, Buckley J, Hughes KS, Gadd M, Specht MC. The safety of multiple re-excisions after lumpectomy for breast cancer. Ann Surg Oncol. 2011 Dec; 18(13):3797-801. View abstract